Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes

Abstract

Purpose

The factors associated with the renal prognosis over six months after the initiation of empagliflozin were compared between the non-elderly and elderly Japanese patients with type 2 diabetes.

Patients and methods

In total, 132 patients treated with empagliflozin (10 mg, once daily) were studied as the safety analysis set. One hundred ten subjects whose medications were not changed during the observation period were investigated as the full analysis set to assess the effectiveness. The subjects were divided into two groups: non-elderly subjects (n=72) of<65 years of age and elderly subjects (n=38) of≥65 years of age.

Results

Although the body weight and HbA1c, AST, ALT and γ-GTP levels were significantly reduced in both the non-elderly and elderly subjects, blood pressure, eGFR and urinary protein excretion were only significantly decreased in the non-elderly subjects. The hemoglobin, hematocrit and serum HDL-cholesterol levels were significantly elevated in both groups. The change in eGFR showed a significant positive association with the change in blood pressure. The change in urinary protein excretion tended to be correlated with the change in blood pressure.

Conclusion

Although renoprotective effects might be limited, empagliflozin can safely and effectively improve metabolic parameters, even in elderly subjects.

Keywords:

• sodium-glucose cotransporter 2 inhibitor
• empagliflozin
• type 2 diabetes mellitus
• elderly
• renoprotection
• renal impairment

Acknowledgment

The authors thank Tomoko Koyanagi and Yoshimi Mogi in the secretarial section of Edogawa Hospital for her valuable help with data collection.

Disclosure

H Ito has received lecture fees from Eli Lilly Japan KK, Boehringer Ingelheim, Takeda Pharmaceutical Company Ltd., Sanofi KK, Novo Nordisk Pharma Ltd., MSD KK, Novartis Pharma KK, Astellas Pharma, Daiichi Sankyo Company, Terumo Corporation, Mochida Pharmaceuticals, Teijin Pharma, Kissei Pharmaceuticals, Kowa Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Sanwa Kagaku Kenkyusho, Dainippon Sumitomo Pharma, AstraZeneca KK, Kyowa Hakko Kirin, Shionogi and Co, Taisho Toyama Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd., and has received consulting fee from Becton, Dickinson and Company. S Matsumoto has received lecture fees from Novo Nordisk Pharma Ltd., Astellas Pharma, and AstraZeneca KK. S Nishio has received lecture fees from Sanofi KK, Taisho Toyama Pharmaceutical Co., Ltd., Kyowa Hakko Kirin, Bayer Yakuhin, Ltd., and Mitsubishi Tanabe Pharma Corporation. S Antoku has received lecture fees from Kyowa Hakko Kirin, Sanofi KK, Kyowa Hakko Kirin, Taisho Toyama Pharmaceutical Co., Ltd., Daiichi Sankyo Company, and Otsuka Pharmaceutical Co., Ltd. S Ando has received lecture fees from Takeda Pharmaceutical Company Ltd. T Izutsu, E Kusano, T Yamasaki, T Mori, M Togane and E Tsugami have no conflicts of interest in this work.